Microvascular Decompression, Teflon, Trigeminal Neuralgia
Conditions
Keywords
Trigeminal Neuralgia, Microvascular Decompression, Teflon Implant, Neurosurgical Techniques, Postoperative Complications, Magnetic Resonance Imaging
Brief summary
The study aims to see if shredded Teflon placed away from the trigeminal nerve is equally effective in pain control in Trigeminal Neuralgia while minimizing the risks of pain recurrence due to granuloma formation when this material is placed immediately close to the nerve in a pledget form.
Detailed description
Complications associated with Teflon implants in the treatment of Trigeminal Neuralgia have been reported, including granuloma formation and persistent neuroinflammation, which can mimic tumor recurrence or lead to renewed symptoms. These concerns underscore the importance of precise implant positioning and accurate volume control. At the reporting institution, the investigators have consistently used a technique involving minimal amounts of shredded Teflon placed around the offending vessel, positioned at a distance from the trigeminal nerve itself. The goal of this technique is to elicit localized arachnoiditis to stabilize the artery and prevent re-compression. To date, no published studies have directly correlated the amount and form of Teflon used with subsequent inflammation and recurrence, particularly with imaging-based validation. The present study seeks to address this gap by retrospectively analyzing the outcomes of microvascular decompression procedures performed using this specific Teflon application method, correlating clinical outcomes with MRI findings to assess the degree of inflammatory response and the likelihood of symptom recurrence.
Interventions
Microvascular decompression for trigeminal neuralgia comparing two different forms to apply the Teflon implant
Sponsors
Study design
Eligibility
Inclusion criteria
* Trigeminal Neuralgia refractory to medical therapy and treated via microvascular decompression
Exclusion criteria
* Other craniofacial neuralgias, atypical facial pain, trigeminal neuralgia (TN) due to non-vascular causes (e.g., multiple sclerosis), and those with posterior fossa pathology, such as tumors, infarctions, hematomas, infections, or inflammatory lesions * Patients treated by alternative methods, including percutaneous radiofrequency thermocoagulation, glycerol injection, balloon compression, or radiosurgery
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Modified Ranking scale | 5 years | The Modified Rankin Scale (mRS) will be used to evaluate neurological disability, ranging from 0 (no symptoms) to 6 (death) |
| Barrow Neurological Institute Pain Intensity Scale | 5 years | The Barrow Neurological Institute (BNI) Pain Intensity Scale will be used to assess pain control, ranging from 1 (no pain, no medication) to 5 (severe pain without relief) |
Countries
Spain
Contacts
Fundación Consorcio Hospital General Universitario de Valencia